A Phase I Study of Dalteparin, a Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multitargeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma

Trial Profile

A Phase I Study of Dalteparin, a Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multitargeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Dalteparin sodium (Primary) ; Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 13 Jul 2016 This trial was completed in Netherlands (end date: 2015-10-14) according to European Clinical Trials Database record.
    • 03 Jun 2014 Interim results (n=19) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top